The Neuroprotective Beta Amyloid Hexapeptide Core Reverses Deficits in Synaptic Plasticity in the 5xFAD APP/PS1 Mouse...

Area of Science:

• Neuroscience
• Molecular Biology
• Pathology

Background:

• Alzheimer's disease (AD) is a leading cause of dementia, with soluble oligomeric amyloid-beta (Aβ) implicated in its early stages.
• Elevated Aβ levels contribute to tau hyperphosphorylation and synaptic dysfunction, hallmarks of AD.
• However, physiological levels of oligomeric Aβ can modulate synaptic plasticity, suggesting a dual role.

Purpose of the Study:

• To investigate the neuroprotective potential of a specific N-terminal Aβ core peptide (N-Aβcore) against synaptic plasticity impairments in an Alzheimer's disease mouse model.
• To elucidate the molecular mechanisms underlying the N-Aβcore's effects on synaptic function.

Main Methods:

• Ex vivo electrophysiology was used to assess hippocampal long-term potentiation (LTP) and long-term depression (LTD) in slices from 5xFAD APP/PS1 mice.
• The N-Aβcore peptide was applied to slices to evaluate its effects on synaptic plasticity and AMPA-type glutamate receptor expression.
• Molecular pathways, including PI3K/mTOR, were investigated to understand the N-Aβcore's mechanism of action.

Main Results:

• The N-Aβcore peptide successfully reversed impairments in both LTP and LTD in hippocampal slices from 5xFAD mice.
• This reversal correlated with the alleviation of downregulated hippocampal AMPA-type glutamate receptors.
• The peptide's action was dependent on a di-histidine sequence and involved the PI3K/mTOR pathway.

Conclusions:

• The non-toxic N-Aβcore hexapeptide demonstrates significant neuroprotective capabilities at the cellular level.
• N-Aβcore can reverse synaptic plasticity dysfunction in an Alzheimer's disease-like model.
• This peptide represents a potential therapeutic candidate for addressing synaptic alterations in Alzheimer's disease.